Success Metrics

Clinical Success Rate
86.4%

Based on 19 completed trials

Completion Rate
86%(19/22)
Active Trials
8(23%)
Results Posted
16%(3 trials)
Terminated
3(9%)

Phase Distribution

Ph phase_3
5
14%
Ph phase_2
2
6%
Ph early_phase_1
2
6%
Ph phase_1
1
3%
Ph not_applicable
11
31%

Phase Distribution

3

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution21 total trials
Early Phase 1First-in-human
2(9.5%)
Phase 1Safety & dosage
1(4.8%)
Phase 2Efficacy & side effects
2(9.5%)
Phase 3Large-scale testing
5(23.8%)
N/ANon-phased studies
11(52.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

86.4%

19 of 22 finished

Non-Completion Rate

13.6%

3 ended early

Currently Active

8

trials recruiting

Total Trials

35

all time

Status Distribution
Active(8)
Completed(19)
Terminated(3)
Other(5)

Detailed Status

Completed19
Recruiting5
unknown5
Active, not recruiting3
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
35
Active
8
Success Rate
86.4%
Most Advanced
Phase 3

Trials by Phase

Early Phase 12 (9.5%)
Phase 11 (4.8%)
Phase 22 (9.5%)
Phase 35 (23.8%)
N/A11 (52.4%)

Trials by Status

active_not_recruiting39%
completed1954%
recruiting514%
unknown514%
terminated39%

Recent Activity

Clinical Trials (35)

Showing 20 of 35 trialsScroll for more
NCT06191133Phase 1

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

Recruiting
NCT07622901Not Applicable

Fasting InTervention for Endometrial Cancer

Recruiting
NCT07436793Phase 2

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

Recruiting
NCT05374720Not Applicable

Analysis of the Molecular Composition of Tubal Cilia in Patients With or Without Ectopic Pregnancy

Terminated
NCT07195305Not Applicable

Radiofrequency Endometrial Ablation or Uterine Artery Embolization for Treatment of Adenomyosis-related Abnormal Uterine Bleeding

Recruiting
NCT04604613

Prediction of Recurrence Among Low Risk Endometrial Cancer Patients

Active Not Recruiting
NCT06816355

Exogenous Sex Hormones and PONV

Completed
NCT06800677

Methylated Biomarkers Predictive of Endometrial Cancer Risk

Active Not Recruiting
NCT05013749Not Applicable

Histerectomy Vs Partial Myometrial Resection for Placenta Accreta Spectrum

Completed
NCT06253832Not Applicable

Conservative Management of Placenta Accreta Spectrum

Completed
NCT04990076

Ultrasound Evaluation of the Myometrium Using the MUSA Terminology Comparison With Histology

Recruiting
NCT04791033

Quality of Life After Hysterectomy (AdenoQOL)

Active Not Recruiting
NCT03694834Early Phase 1

Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer

Terminated
NCT04120649

Different Risk Stratification Models for Prediction of Lymph Node Involvement in Endometrial Carcinoma

Completed
NCT05261165

Effect of a Uterine Manipulator on the Incidence of Lymphovascular Propagation (LVSI) in Treatment of Endometrial Cancer

Completed
NCT03018249Early Phase 1

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

Completed
NCT04830085Not Applicable

Factors Associated With Adenomyosis and a Clinical Scoring System for the Diagnosis

Completed
NCT02260752

Patient Centered Results for Uterine Fibroids

Completed
NCT03748693

Inflammation and Cellular Immunity in Vaginal Tissue in Patients With Pelvic Organ Prolapse

Unknown
NCT03698604Not Applicable

Total Laparoscopic Hysterectomy Versus Total Abdominal Hysterectomy in Women With Endometrial Neoplasia

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
35